Scrutinise the evidence on any medicine.

AI evidence synthesis, built for medicine. For those who need to know when the evidence moves.

Upadacitinib (Rinvoq) · Atopic Dermatitis · Weekly claim register · Cycle W19 2026 Updated this cycle

Claim	Verdict	Movement	Score
Efficacy
UPA 30mg achieves superior EASI-75 vs placebo in moderate-to-severe AD	Definitive	— Stable	88%
IGA 0/1 clear or almost-clear skin achieved at week 16	Definitive	— Stable	89%
Rapid itch relief within 2 weeks is superior to dupilumab	Likely	↑ Strengthening	82%
Sustained EASI-75 response maintained at week 52	Likely	— Stable	73%
Comparative Efficacy
UPA 30mg achieves deep response superior to dupilumab at week 16	Likely	↑ Strengthening	85%
EASI-75 response rate is non-inferior to tralokinumab at week 16	Likely	— Stable	79%
Head-to-head superiority over lebrikizumab on itch NRS at week 12	Uncertain	— Stable	52%
Safety
Serious infection rate is not elevated vs dupilumab over 52 weeks	Definitive	↑ Strengthening	86%
Acne incidence is higher with UPA 30mg vs dupilumab in adolescents	Likely	— Stable	74%
Class-level Safety
Long-term cardiovascular risk is not elevated vs dupilumab in AD patients	Uncertain	— Stable	48%
Malignancy incidence is not elevated above background in the AD indication	Doubtful	↓ Weakening	31%

What Scrutinise delivers

Scientific intelligence delivered when you need to know.

Weekly · Per medicine

Claim register

Every scientific claim behind your medicine, scored on a five-tier verdict scale and flagged for movement. Organised by cluster — efficacy, safety, comparative, class-level, real-world.

ID	Claim	Verdict	Movement	Score
EFF-04	UPA 30mg achieves deep response superior to dupilumab at week 16	Likely	↑ +7pp	85%
CCT-04	Malignancy incidence is not elevated above background in AD	Doubtful	↓ −5pp	31%
EFF-05	Rapid itch relief within 2 weeks superior to dupilumab	Likely	—	76%

Monthly · Per indication

Competitive intelligence

A hub-and-spoke matrix scoring all active comparators against a reference medicine across the endpoints that matter in clinical and payer conversations. Signal movers flagged each cycle.

Medicine	EASI-75	Deep resp.	Serious AEs	Itch relief
UPA 30mgRinvoq	78% H2H	85% ↑	54%	70%
LebrikizumabEbglyss	22% ↓	28%	48%	45%
NemolizumabNemluvio	44%	38%	52%	72% ↑

On request · Per cluster

Evidence gap report

A structured analysis of every open evidence gap in your medicine's claim landscape — classified by type, prioritised by HTA and commercial relevance, with a recommended study design for each.

High priority · Class contamination

Long-term CV and malignancy — JAK class in AD

No H2H long-term safety data vs dupilumab. Primary vulnerability in PBAC and payer conversations. Study required: long-term OLE reporting CV and malignancy by indication.

Medium priority · Methodological

NMA ranking instability — deep response endpoint

NMA pooled across heterogeneous trials. Score directionally correct but wider CIs than H2H. One further head-to-head trial would convert this to a robust lead.

Pre and post-conference · Per meeting

Conference brief

A rapid scan of every major congress — EADV, ECCO, ACC, ASCO, and others — identifying the abstracts and late-breaking data most likely to shift your evidence landscape before the papers publish.

High impactEADV 2026 · Late-breaking

Nash 2025 integrated safety analysis — 27,000 patient-years across all UPA indications

High impactEADV 2026 · Oral abstract

JADE Compare extension — abrocitinib long-term H2H data vs dupilumab at 104 weeks

WatchEADV 2026 · Poster

Lebrikizumab real-world registry data — itch response in biologic-naive patients

Request access

Scrutinise the evidence on any medicine.

Scientific intelligence delivered when you need to know.

We work with a small number of pharmaceutical teams at a time.